Supporting the

Neuroendocrine Cancer Community

UK & Global Research – Current and Completed Trials

Jul 14, 2022

Last updated 2021

CURRENT TRIALS

To learn more about any of the listed studies / trials, you or your doctor may contact the study research staff using the point of contact information provided. If this is a formally listed trial please refer to it by its study number: NCT number. You can confirm a study / NCT number by looking it up on either ClinicalTrials.gov or the NIHR database.

If uncertain how to do this or you have a question about clinical trials and how to find more information – you can check “How To” here. or contact us.

On this page you will find a list of UK, European and Global trials (Global includes UK). For further information about each trial – click the trial number link. On each trial page you will find out more about the trial, which centres/hospitals are involved and the trial co-ordinator contact details.

NCUK is not involved in recruitment for trials – this page is for information only – please talk with your specialist team if you find a trial you would like to be considered for.

  • “Start date” is the estimated or actual starting date of the trial 
  • “Estimated completion date” is the estimated date the trial will end. 

Please note recruitment for the trial may finish before this date.

 

Trial Name Trial number (region)

Link / Further details

NEN indication – see trial page for more information Start date Estimated completion date
1188TiP NICE-NEC GETNE-T1913 (Spain) Grade 3 Neuroendocrine Neoplasms (incl NET & NEC) – GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) or CUP (unknown primary) 2019 Unknown
18F-AlF-NOTA-octreotide PET/CT NCT03511768 (China) Neuroendocrine Neoplasms (incl NET & NEC) -imaging trial – trial status unknown
68Ga-NOTA-exendin-4 PET/CT NCT02560376 (China) Insulinoma (and Nesidioblastosis) – imaging trial – trial status unknown
Anlotinib and AK105 NCT04207463 (China) GI, Urinary System & NET G1-2 GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) June 2020 May 2021*
ARROW NCT03037385 (Global) Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors – Medullary Thyroid Carcinoma – may incl other NENs -see eligibility criteria March 2017 February 2024
ARTISAN NCT04362436  (UK) Metastatic NET (NET that has spread to the liver) January 2019 September 2022
ATLANT NCT02698410 Completed
AXINET (GETNE-1107) NCT01744249 (Europe) Well-differentiated non-Pancreatic Grade 1-2 NET. Not recruiting
BETTER2 NCT03351296 (France) Well-differentiated Pancreatic NET Grade 1-3 February 2018 February 2025
BEVANEC NCT02820857 (France) Poorly-differentiated NEC CUP (unknown primary) or GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) February 2017 February 2024
BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer(SCNC) or adenocarcinoma phenotype NCT03910660 (USA & UK) Small Cell Neuroendocrine Prostate Cancer – see eligibility criteria February 2019 June 2022
CABATEN NCT04400474 (Spain) Basket trial NENs + Endocrine Cancer : incl well-differentiated lung & thymus NET, Adrenocortical Carcinoma (ACC), Pheochromocytomas & Paragangliomas and Grade 3 Neuroendocrine Neoplasms (NET & NEC – non-Small Cell) – GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) October 2020 March 2024
CABINET NCT03375320 (USA) metastatic NET – Grade 1-2 NET : GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) +  Typical & Atypical Lung & Thymus July 2018 January 2022
CABOAVENEC NET G3/NEC with low Ki67
CABONEN NCT04524208 (Germany) Advanced, Low Proliferative Neuroendocrine Neoplasms (NET & NEC) G3 – Ki67 20-60% December 2020 June 2023
COMPETE NCT03049189 (Global) Well-differentiated NET – non-functioning GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) + functioning pancreas February 2017 June 2029
CONTROL NETS NCT02358356 (Australia) GEPNETs (small bowel & pancreas only) G1-2 . Trial status unknown
DUNE NCT03095274 (Spain) Grade 1-2 NET GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) and Lung (Typical & Atypical Ki67 <20%) and Grade 3 NEC GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) and CUP (unknown primary) April 2017 July 2021
EVINEC NCT02113800 (Germany) Completed
Feasibility & safety of robotic-assisted pancreatectomy jRCTs022180048 (Japan) Operable pancreatic neoplasms – benign and malignant : includes Pancreatic NET March 2018
FOLFIRINEC NCT04325425 (France) Grade 3 NEC or MiNEN (see eligibility criteria) – GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) and CUP (unknown primary) September 2020 September 2026
Gallium-68 Labeled LM3 PET/CT NCT04318561 (China) Well -differentiated NETs (imaging) December 2019 December 2021
IGNYTE NCT03767348 (USA & UK) Study of RP1 Monotherapy and RP1 in Combination With Nivolumab – Skin – incl Merkel Cell Carcinoma – for whom anti-PD1/PD-L1 therapy is indicated September 2017 November 2024
Image-Enhanced Endoscopy in the Gastrointestinal Tract NCT04085211 (UK) Patients with an established history of gastric neuroendocrine tumours requiring surveillance July 2019 May 2022
Ipilimumab and Nivolumab NCT02923934 (Australia) Rare Cancers incl NETs (pancreas, small bowel and lung – Typical and Atypical) Not recruiting
LIBRETTO-001 NCT03157128 (Global) Study of LOXO-292 (Selpercatinib) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer May 2017 November 2023
LIBRETTO-531 NCT04211337 (Global) Selpercatinib (LY3527723) in Medullary Thyroid Cancer February 2020 November 2026
LOLA NCT04427787 (Italy) Well-differentiated NET GEP (stomach, pancreas, small bowel & rectum), Lung (Typical & Atypical) & Thymus – Ki67 10% June 2020 November 2023
LUTHREE NCT03454763 (Italy) SSTR2 positive tumours May 2016 May 2020*
MGMT-NET NCT03217097 (France) MGMT status in NENs : Well-differentiated NET Grade 1-3 – duodenal, pancreatic, lung and thymus (Typical and Atypical) and CUP (unknown primary) October 2018 November 2021
MiBG therapy jRCTs041190085 (Japan) NETs with positive MiBG uptake November 2019
Mobile App NCT04324502 (UK) Mobile App – patient self-management tracking and Patient Reported Outcome & Quality of Life Monitoring July 2020 July 2026
NEO-NEC NCT04268121 (Not stated) Poorly differentiated NEC Digestive (see eligibility criteria) September 2020 March 2024
NET 02 NCT03837977 (UK) Poorly differentiated NEC – not lung November 2018 CLOSED
NETFIT Spain GETNE Wearables in GEPNET
NETTER2 NCT03972488 (Global) Grade 2-3 well-differentiated GEP NET (stomach, pancreas, small bowel, large bowel, rectum & appendix) – see eligibility criteria January 2020 December 2026
NIPINEC NCT03591731 (France) Poorly-differentiated NEC : GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix), Large cell NEC Lung and MiNEN (NEC component >70%) – see eligibility criteria January 2019 September 2023
OCLURANDOM NCT02230176 (France) Well-differentiated Pancreatic NET – see eligibility criteria February 2015 October 2023
Olaparib + temozolamide NCT04394858 (USA) Pheochromocytomas and Paragangliomas – see eligibility criteria November 2020 February 2023
PaC-MAn (Tissue Collection Study) NCT03840460 (UK) early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour. January 2019 January 2023
PALBONET NCT02806648 Completed
Phase I Study of CC-90011 NCT02875223 (Europe & UK) Phase I study of CC-90011 in subjects with advanced unresectable solid tumors (incl grade 2 NENs, grade 2 NETs and NECs), Small Cell Lung Cancer  and Non-Hodgkins Lymphoma August 2016 October 2024
PODIUM-201 NCT03599713 (Global incl UK) Merkel Cell Carcinoma February 2019 March 2023
Post-Authorization Safety Study (PASS) of LysaKare® NCT04524442 (Europe & UK) Somatostatin receptor positive GEP-NETs (stomach, pancreas, small bowel, large bowel, rectum & appendix) – who are eligible for Lutathera (PRRT with Lutetium) – study is to evaluate the effect of arginine/lysine solution administration on serum potassium levels. January 2021 November 2021
PREF-NET NCT04649580 (UK) NETs GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) Prescribed Somatuline® Autogel® In A Homecare Setting April 2021 September 2021
PRELUDE NCT02788578 (Global) Stopped – insufficient recruitment
PRRT & capecitabine CTRI/2020/01/022636 (India) Well-differentiated NET GEP (stomach, pancreas, small bowel & rectum) – see eligibility criteria January 2020 (January 2022)
PRRT in receptor +ve Lung NENs NCT04665739 (Global) Grade 1-2 Lung (Typical & Atypical) see eligibility criteria July 2021 July 2024
REMINET NCT02288377 (Europe) Completed
RETNET NCT02724540 (Global) Bland vs Chemo embolisation in NET that has spread to the liver March 2016 March 2024
RMPanNET NCT04066322 (China) Well-differentiated pancreatic NET – see eligibility criteria August 2019 July 2025
SALUS NCT03691064 (USA, Portugal & UK) Adult patients treated with LUTATHERA (PRRT with Lutetium) for the labeled indication using the approved dosing regimen – Post-Authorisation (eg since regulatory approval) November 2018 December 2024
SANET-ep NCT02588170 (China) Xu (2020) (SANET-ep) Lancet Oncol. Not recruiting
SANET-p NCT02589821 (China) Xu (2020) (SANET-p) Lancet Oncol.  Not recruiting
SENECA NCT03387592 (Italy) NEC : GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix) , Lung, CUP (unknown primary) and Genitourinary, Gynaecological and Laryngeal NECs may be included – see eligibility criteria March 2017 January 2022
SEQTOR NCT02246127 (Europe) Advanced Pancreatic NET. Not recruiting.
SIRT NCT04362436 (United Kingdom) TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (ArTisaN) January 2019 September 2022
SORAFENIB NCT00390325 (USA) Medullary Thyroid Cancer : USA. Not recruiting
STARTRK-2 NCT02568267 (Global) Basket study of Entrectinib (RXDX-101) for the treatment of patients with solid tumours that harbour an NTRK1/2/3, ROS1, or ALK gene fusion. November 2015 December 2024
SUMMERTIME NCT04705389 (Global incl UK) Merkel Cell Carcinoma (biomarkers) September 2021 September 2023
SUNEVO NCT02402062 (Spain) Completed
SURUFATINIB NCT04579679 (Europe)

 

 

NCT04579757 (USA)

 

 

 

NCT02549937 (USA)

NET incl Small bowel & lung – other sites – see eligibility criteria 

 

Advanced solid tumours incl Grade 1-2 GEP (stomach, pancreas, small bowel, large bowel, rectum & appendix), Lung, Thymus and SCLC.

 

Advanced solid tumours incl Non-lung NET

May 2021

 

 

March 2021

 

 

 

November 2015

October 2022

 

 

April 2023

 

 

 

November 2021

Surufatinib With Toripalimab NCT04169672 (China) Advanced Solid Tumors incl NENs – see eligibility criteria December 2019 February 2022
TALENT NCT02678780 (Europe) Completed
Topotecan With M6620 NCT03896503 (USA) Small Cell Lung Cancer – see eligibility criteria August 2019 September 2023

 

BIOMARKERS and OTHER INITIATIVES

NETest

Trying to find the best investigation to get the most relevant information about what is happening to your Neuroendocrine Cancer is really important, so that the right diagnostic, treatment and follow up plans can be made. ‘NETest’ is a potentially new way of assessing and monitoring Neuroendocrine Cancer through a blood test.

Research is always moving forward to find potentially new, more specific and less invasive tests that can be used to let your specialist team know what the activity of your Neuroendocrine Cancer.

The NETest is a blood test and may provide this information.

Whilst there are no formal clinical trials into the NETest in the UK at this time (2021), there are several ENETS Centres of Excellence that are using the NETest, as part of their routine follow-up of NET patients – to assess its efficacy and accuracy.

NETest® A Non-Invasive, Test for Neuroendocrine Tumour Patients

The NETest is an in vitro MultiAnalyte with Algorithm Analyses (MAAA) test service, performed in certified clinical laboratories, that assesses targeted gene expression profile of RNA isolated from peripheral blood. NETesting is intended to aid in the identification of active disease and therefore provide an assessment of treatment responses in neuroendocrine tumour patients at the time of testing in conjunction with standard clinical assessment. Indicated for use in patients: 18 years of age or older.

* Disease activity is defined as the calculated risk of highly active disease as measured by an algorithm based on gene expression data. NETest results should be used in conjunction with standard clinical assessment.

FIND OUT MORE – https://www.wrenlaboratories.com

ORDERING A NETest IN THE UK: Please note that there is a fee payable for this test.

You can ask you doctor about having the NETest : to do so s/he will need to visitWren laboratories website:  https://wrenlaboratories.com/and Click on the “Order EU Kit” button. They will need to register (if not already signed up) – and there may be a fee to be paid to process the request, if your doctor is not part of one of the teams trialling this test at present. If you or your doctor have any questions, call: +12032083464 or email:

enquiries.europe@wrenlaboratories.com

***Please note the information above is commercial information provided by an external source and not from Neuroendocrine Cancer UK.**

Related article on the history of biomarkers up to and including the NETest:

Kjell Oberg (2021) Molecular Genomic Blood Biomarkers for Neuroendocrine Tumors: The Long and Winding Road from Berzelius and Bence Jones to a Neuroendocrine Destination.
Neuroendocrinology 2021;111:297–303

 

Innovation

AdVince is a potential treatment for a form of neuroendocrine cancer currently being tested at Sweden’s Uppsala University. AdVince gets its name from the ‘adenovirus’ (a harmless virus causing the common cold), modified by a team of Swedish scientists to develop their therapy, and Vince Hamilton, the generous patron who helped finance the trials.

2018 A status update on the crowdfunded clinical trials of AdVince, a genetically engineered virus which targets and kills neuroendocrine cancer cells.- watch video here.

Oncolytic viruses engineered to selectively kill tumor cells have exhibited activity in melanoma and head and neck cancers. AdVince – for the treatment of liver metastases from Neuroendocrine Cancer was developed and is now being evaluated in a phase I/IIa clinical trial for patients with liver dominant NETs of GEP or bronchial origin (NCT02749331).

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy (RADNET)

This is an open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.

NCT number : NCT02749331
Principal Investigator : Professor Kjell Oberg

READ MORE

PUBLISHED RESEARCH and FURTHER UPDATES

Research undertaken by Neuroendocrine Cancer UK – in-house and in partnership with clinical experts: published articles can be found and read here.

For updates and further information about recently published trial data & innovation articles – join our online community or sign up for our newsletter here – You can also check our News section.